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Abstract: Breakthrough pain, a transitory severe pain with the background of otherwise 
controlled persistent pain has a prevalence between 52% and 67% in outpatients with cancer. 
Medications for such sudden-onset pain require non-invasive delivery of a potent and short-acting 
opioid for rapid pain relief. Although oral transmucosal delivery of fentanyl citrate (OTFC) 
has been shown to provide better pain relief than a typical oral opioid administration such as 
morphine sulfate immediate release (MSIR) in the management of breakthrough pain in patients 
with cancer-related pain, newer delivery systems offer a potential for further enhancement of 
pain relief. The fentanyl effervescent buccal tablet (FBT) formulation employs a novel drug 
delivery system that relies on an effervescence reaction to improve buccal fentanyl absorption. 
Using the effervescence reaction results in the production and dissipation of carbon dioxide 
with a dynamic shift in pH as the tablet dissolves. The induced low pH favors dissolution of 
fentanyl citrate in saliva (higher water solubility). The subsequent increase in pH thereafter 
favors the buccal absorption of non-ionized fentanyl across the buccal mucosa. Such a pH 
“pumping” mechanism increases the permeation of fentanyl into and through the buccal to the 
vascular system from where the agent is transported to the speciﬁ  c opioid receptor sites in the 
CNS. Compared with OTFC, data in healthy volunteers show that the effervescence reaction 
employed in FBT increases the total amount and the speed of absorption of fentanyl being 
absorbed. Compared with OTFC there is an increase in peak fentanyl blood concentrations, 
and an enhancement of the amount of buccal delivery of fentanyl. Such favorable data are 
underlined by the results of clinical studies where the FBT technology was studied in patients 
with breakthrough pain in chronic malignant pathologies.
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Introduction
Breakthrough pain is a transitory ex  acerbation of pain commonly associated with 
pain management in cancer patients.1,2 It has a prevalence between 52% and 67% in 
otherwise well-con trolled, persistent cancer-related pain,3,4 and up to 89% in palliative 
cancer units.5 It is often induced by weight bearing/excessive movement, during defeca-
tion/urination, coughing, while eating or even spontaneously without any known cause, 
sometimes reﬂ  ecting an end-of-dose failure.4,6,7 Although breakthrough pain is hetero-
geneous, with a somatic, visceral or neuropathic origin, it is usually similar in etiology 
and pathophysiology to persistent pain showing a moderate to severe intensity. Because 
of all these features breakthrough pain demands immediate and adequate relief.
With a mean frequency of 1 to 4 episodes/day, a mean time to peak effect of 3 to 
10 minutes and a mean duration of 15 to 60 minutes,1,8 such episodic increase in pain 
intensity demands a fast-acting therapeutic regimen. Although relief from break-
through pain can be derived from general measures, such as changing position, hot and Journal of Pain Research 2009:2 14
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cold compresses, massage, counseling and/or non-analgesics, 
such practices provide modest relief at best.9,10 Therefore the 
current approach in the management of patients with chronic 
cancer pain and breakthrough pain involves a medication 
on top of the basic opioid, with a rapid onset, and a short 
duration of action, permitting titration to effect. In addition, 
it should induce only minimal side effects, and should be 
applied by the patient by mouth.5,11 Because the oral route 
is the most convenient mode of application, a variety fast-
acting opioids have been developed, all of which, however, 
demonstrate a mismatch  between the temporal characteristics 
of breakthrough pain and the onset of analgesia associated 
with standard, short-acting, orally administered opioids. 
Conventionally treated with a supplemental pro re nata (PRN) 
dose of a fast-release tablet or oral solution of morphine, 
the agents have a low lipophilic proﬁ  le, which results in a 
slow permeation through the blood–brain barrier taking up 
to 60 minutes till maximum efﬁ  cacy.12 Although a novel 
formulation of morphine with an effervescent delivery system 
(Painbreak®, Riemser Company, Germany) displays a faster 
onset of action than the immediate-release formulation,13 
oral transmucosal fentanyl citrate (OTFC) has become a 
mainstay in the treatment of breakthrough pain,14 because 
it provides faster absorption of the lipophilic fentanyl than 
any other oral formulation.9 However, there are limitations 
of this formulation including conveniency in an outpatient 
setting as the fentanyl stick does require a handle for swab-
bing along the buccal surface, a dental decay because of its 
sugar content, and a time span to become effective that still 
is far from being optimal.8,15,16
Therefore, a new formulation of fentanyl, the fentanyl 
buccal tablet (FBT), was designed to provide an even faster 
onset of analgesia. The buccal tablet has been approved 
by the FDA and has been marketed in the US since 2006 
under the brand name Fentora® (Cephalon, Inc., Salt Lake 
City, Utah, USA) for the treatment of breakthrough pain 
in opioid-tolerant cancer patients using standard regular-
release opiates. In April 2008 the EMEA approved FBT 
in Europe for the same indication, under the brand name 
Effentora™. Although OTFC is effective in this indication 
because of its rapid onset of action, the newly approved 
formulation offers certain advantages. Further reﬁ  nements 
of the fentanyl formulation were made in order to increase 
patient compliance, while at the same time increasing trans-
mucosal absorption of fentanyl across the buccal mucosa, 
resulting in a further shortening in onset of action and an 
increase of the amount of the opioid being absorbed into 
the bloodstream.17 In addition, the inconspicuous use of the 
buccal tablet by patients in public when there is an incidence 
of breakthrough pain results in a higher comfort.
FBT displays a further increase in onset of action over 
the OTFC solid drug–matrix formulation. In order to achieve 
these advantages practical considerations that affect the 
microenvironment adjacent to the dissolving of FBT need 
to be borne in mind. Patients are instructed to place the 
buccal tablet above a molar tooth between the upper cheek 
and allow it to dissolve for approximately 14 to 25 minutes 
(Figure 1). FBT has a mildly bitter taste, and if the tip of 
the tongue is placed on a dissolving tablet, a slow “ﬁ  zzing” 
sensation similar to that produced by a carbonated beverage 
Figure 1 The principle of placing a fentanyl effervescent buccal tablet in the cheek pouch.Journal of Pain Research 2009:2 15
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may be experienced. After 30 minutes, if remnants from the 
buccal tablet remain, they may be swallowed with a glass 
of water. The buccal tablet should not be sucked, chewed or 
swallowed, as this will result in lower plasma concentrations 
than when taken as directed.
Formulation of the FBT
for breakthrough cancer pain
Similar to the oral morphine effervescent formulation 
Painbreak®, effervescence can be of use as a penetration 
enhancer.18 The basic principles of action of an effervescent 
formulation are to
–  open tight junctions of the mucosal barrier,
–  increase the hydrophilic nature of the solvent by an 
enhanced penetration through the water layer of the buccal 
membrane
–  increase the ﬂ  uid volume with a drag effect through the 
mucous membrane.
In principal, by adding citric acid and sodium bicarbonate 
to the lipophilic opioid fentanyl, and making contact with 
saliva, carbon dioxide is released, which dissolves to form 
carbonic acid, ensuring a decrease of pH and an increase 
in water solubility of fentanyl. This process decreases pre-
existing ions (cations as well as anions), which are now 
forced to form molecules, being neutral on the outside. 
Since passive diffusion of the active ingredient fentanyl 
increases proportionally with the higher amount of uncharged 
molecules, higher amounts of fentanyl will penetrate through 
the unstirred water layer of the mucous membrane.
Proof for the above hypothesis has been demonstrated in 
clinical studies using this Oravescent® Technology (CIMA 
Labs, Inc., Eden Prairie, MN, USA). There was an intial 
faster rise in serum levels and a more complete absorption 
of fentanyl, resulting in a quicker onset of action, which is 
of advantage in breakthrough cancer pain.19 In this study 
kinetics of FBT demonstrated proportionality of dosages 
ranging from 200, 500, 810 to 1080 μg in healthy human 
volunteers, with a faster onset and higher maximum serum 
fentanyl concentration compared with a similar dose to the 
conventional transmucosal fentanyl citrate (Figure 2).
Pharmacokinetic parameters 
of fentanyl effervescent buccal 
tablets in adults
After being absorbed into the blood stream, and contrast to 
morphine, fentanyl enters the central nervous system (CNS) 
much faster because it rapidly crosses the blood–brain barrier 
once it enters the systemic circulation.20 The rate constant 
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Figure 2 Serum fentanyl concentrations after administration of fentanyl effervescent buccal tablets (FBT) 200 μg, fentanyl 200 μg tablets without effervescent agents, compared 
with oral transmucosal fentanyl citrate (OTFC) 200 μg. Adapted from.19Journal of Pain Research 2009:2 16
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for the equilibrium of fentanyl between the blood and CNS 
is 6 minutes,20 whereas the same rate constant for morphine 
is approximately 17 minutes.21 The novel formulation of 
FBT therefore results in a pharmacokinetic proﬁ  le that is 
expected to provide greater clinical beneﬁ  ts in breakthrough 
cancer pain than OTFC. For example, in clinical studies FBT 
is rapidly absorbed with a Tmax – an indicator of the time to 
maximum analgesia – of 46 minutes (Figure 3, Table 1), in 
contrast to OTFC, which has a Tmax of 91 minutes. Mean 
serum concentrations show a biexponential decline after the 
peak levels after FBT at a dose 400 μg.17 However, individual 
proﬁ  les for approximately half of the subjects in these studies 
show a triexponential decline, which is consistent with the 
known pharmacokinetic proﬁ  le of fentanyl. Then the agent 
is rapidly distributed from the serum to highly perfused tis-
sues such as the brain, heart and lungs, and then redistributed 
back to the plasma.17 It is the rapid distribution to the brain 
that is presumed to account for the fast onset of action of a 
fentanyl-induced analgesia.
The initial distribution half-life to the lower perfused tis-
sues is followed by an elimination/gastrointestinal absorp-
tion phase and a slower phase of distribution to the deep 
tissue compartments. This tissue distribution, combined 
with biotransformation in the liver by the CYP3A4 enzyme 
system, results in the formation of inactive norfentanyl, 
and an appropriate decline in plasma concentrations below 
clinically relevant threshold levels.22 Fentanyl has been 
chosen for transmucosal delivery in the FBT formulation 
because it has a high bioavailability of 65% (±20% SD) 
combined with a high fraction being absorbed via the 
mucous membranes of 48% (± 31.8% SD).23 Additional 
studies demonstrate that the plasma Cmax of FBT increases 
in a dose-proportional manner over a dose range of 100 to 
800 μg (Table 1).
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Figure 3 Effect of fentanyl buccal tablet (FBT) and placebo on: A. Pain intensity difference and B. Pain relief in opioid-tolerant patients with breakthrough pain associated 
with chronic cancer pain. Adapted from.31Journal of Pain Research 2009:2 17
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At doses between 100 to 800 μg of FBT the area 
under the curve (AUC 0 − t) and Cmax show a linear 
proportional relationship to the administered dose, with a 
median time to maximum concentration (Tmax) in the range 
of 35 to 45 minutes. In addition, a single-dose study of 
270 to 1300 μg for dose proportionality found an overall 
dose effect, and for dosages greater than 810 μg showed a 
less-than-dose-proportional increase in Cmax.25 Such effects 
might be attributed to saturation at the site of administration 
at the buccal mucosa, because administration of four 100 μg 
tablets in contrast to one single 400 μg tablet produces 
slightly higher AUC values. Such differences might be due 
to the higher surface area of the tablet coming into contact 
with the buccal mucosa.23
Two pharmacokinetic studies compared the different 
proﬁ  les of FBT and OTFC. FBT demonstrated a signiﬁ  cant 
faster rate (Tmax) and a signiﬁ  cant greater extent (Cmax and 
AUC 0 − ∞) of fentanyl movement into the systemic 
circulation.25 Although the Tmax of the effervescent fentanyl 
delivery system is longer than onset-to-pain-intensity peak 
time of breakthrough pain, the new formulation has certain 
advantages. With a median Tmax of 47 versus 91 minutes and 
a higher bioavailability of 65% versus 47%, such data favor 
FBT.26 Together with these favorable pharmacokinetic data 
and assuming that opioid blood concentrations are closely 
related to clinical effect,27 FBT allows a more straightforward 
titration of the opioid fentanyl to achieve the desired anal-
gesic level. Although the observation that multiple dosing 
with FBT shows predictable pharmacokinetics, which also 
contributes to the ease of dose titration,17 a faster clinical 
effect, based on a shorter Tmax, can only be assumed. Further 
studies are therefore needed to substantiate such an effect.
The variation in the time taken for FBT to dissolve in 
the buccal pouch – also called the ‘dwell time’ – has led to 
the question of whether such variability affects absorption 
of FBT, which may be of relevance to subsequent plasma 
levels.28 Post-hoc analysis of the pharmacokinetics of FBT 
in healthy volunteers indicates that the rate and extent of 
fentanyl absorption are not affected by the time taken for 
complete dissolution in the buccal cavity.28 Such ﬁ  ndings 
suggest that any residue left in the buccal cavity is inactive 
and that variability in dwell time is not likely to be important 
for achieving the desired analgesic effect. Therefore, patients 
are instructed to swallow with water any of the buccal tablet 
remaining after 30 minutes. Although the primary pharmaco-
kinetic studies with fentanyl buccal tablets have been carried 
out in healthy volunteers, other studies involving cancer 
patients with (n = 8) or without (n = 8) clinical and functional 
grades of mild mucositis (grade 1) revealed that the absorp-
tion proﬁ  le of FBT 200 μg was similar in both groups.29 The 
results indicate that FBT can also be considered in opioid-
tolerant patients who also exhibit mild mucositis.
Clinical efﬁ  cacy of oral FBT
in patients with breakthrough pain
The clinical efﬁ  cacy of FBT in treating breakthrough pain 
associated with cancer pain has been well established in 
two randomized, placebo-controlled trials in opioid-tolerant 
cancer patients. The two studies, one with 123 patients30 the 
other with 125 patients,31 received FBT in a double-blind 
fashion. Both documented clinically signiﬁ  cant improvement 
in pain scores versus placebo (Figure 3). The signiﬁ  cant 
greater reduction (p  0.05 and p  0.0001, respectively) 
in pain intensity was achieved after FBT administration 
compared with placebo as early as 15 and 10 minutes, respec-
tively. Interestingly, patients with moderate or severe pain 
at baseline generally experienced greater improvements in 
pain than those with mild pain.
In these studies, for 35% of FBT-treated episodes, the 
efﬁ  cacy at 60 minutes was rated as ‘very good’ or ‘excellent’. 
Also, use of supplemental medication for pain relief occurred 
more frequently during episodes of breakthrough pain 
when patients received placebo (50%) than with FBT (23%). 
In these studies the beneﬁ  cial effect of an effervescent 
Table 1 Pharmacokinetic properties of different single doses of fentanyl effervescent buccal tablets
Dose
(μg)
Tmax h
(median, 90% CI)
Cmax ng/mL
(mean ± SD)
t1/2 h
(median, 90% CI)
AUC 
0 – Tmax(ng * h/mL)
AUC 
0 – ∞(ng * h/mL)
100 0.75 (0.4–3.02) 0.25 (0.14) 2.63 (1.5–13.6) 0.80 (0.26) 0.98 (0.37)
200 0.67 (0.33–3.0) 0.40 (0.18) 4.43 (1.9–20.8) 1.39 (0.46) 2.11 (1.13)
400 0.58 (0.33–3.0) 0.97 (0.53) 11.1 (3.4–20.6) 2.90 (0.92) 4.72 (1.95)
800 0.67 (0.4–3.0) 1.59 (0.90) 11.7 (4.6–28.6) 5.27 (1.85) 9.05 (3.72)
Adapted from.24
Abbreviations: CI, conﬁ  dence interval; SD, standard deviation;   AUC, area under the curve.Journal of Pain Research 2009:2 18
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fentanyl delivery system to a clinical endpoint of pain relief 
was compared only with placebo. Thus, there is the need 
to demonstrate its effect in further studies, comparing the 
clinical beneﬁ  ts with other compounds.
In the studies with FBT as well as in other studies where 
breakthrough pain was treated with an orally fast-acting mor-
phine tablet,32 an effervescent solution13 or with OTFC,33,34 
there was no simple linear relationship between the effective 
dose and the dose of the background opioid regimen. Not 
only does such an approach lack a solid base of evidence, 
but also accumulating data suggest that the optimal dose of 
breakthrough pain medication may bear little relation ship to 
the around-the-clock dose.31 Such results underline the need 
to titrate individually to effectiveness rather than calculate 
the percentage of an existing opioid regimen as previously 
suggested.33,35,36
Safety and tolerance of the FBT
In both reported placebo-controlled studies, the most 
commonly observed adverse events were typical of those 
observed with other opioid medications, with the exception 
of application-site reactions (Table 2).
The obvious difference in side effects between the studies 
of Slatkin and of Portenoy may well be attributed to the dif-
ference in around-the-clock and supplemental medication. 
For instance, in Portenoy’s study37 most patients used either 
a fentanyl transdermal formulation (28%), morphine (34%) 
or oxycodone (36%) extended release as their basic opioid 
medication. Most patients in the Slatkin study31 used either 
oxycodone, an oxycodone–acetaminophen combination 
(54%), or the fentanyl patch (32%) while only 20% took 
morphine as their basic medication. The well established 
fact that morphine alone results in a higher percentages 
of side effects than other opioids, especially in an elderly 
population,38,39 may account for the difference in the percent-
age of observed effects.
Another potential serious side effect is respiratory depres-
sion. No data on serious adverse events from respiratory 
depression and/or chest wall rigidity were observed in clinical 
trials, nor have they been found in the available literature in 
patients following correct dosing of FBT.30,31,40
Switching from OTFC 
to FBT – dosing recommendations
The important consequence of the novel formulation of the 
FBT is that the bioavailability of fentanyl is higher than 
with an equivalent dose of OTFC.23 Such a difference has 
to be taken into consideration when wanting to switch from 
OTFC to FBT for breakthrough pain episodes. In a crossover 
study in healthy volunteers, an ∼30% smaller dose of FBT 
achieved systemic exposure comparable to OTFC, although 
signiﬁ  cant individual variation was observed.23 Such ﬁ  nd-
ing should be taken into consideration when switching 
patients between these two formulations in order to prevent 
patients from being subjected to inappropriately high or 
low systemic levels of fentanyl. Because FBT is available 
in tablets strengths of 100, 200, 400, 600 and 800 μg, and 
taking into account a 30% smaller dose of FBT than OTFC, 
switching therefore can be tailored to the patient’s individual 
requirements. This, however, is followed by an up or down 
dose titration to provide effective analgesia while avoiding 
adverse side effects.
The initial dose of FBT in breakthrough cancer pain is 
100 μg. Titration should start with one 100 μg tablet and 
should subsequently be performed with the 200 μg tablet 
and multiples of this tablet strength, ie, the patient should 
use two 200 μg tablets with one on each side of the mouth 
in the buccal cavity or three 200 μg tablets with one on one 
side of the mouth in the buccal cavity and two in the other 
side or two 200 μg tablets on each side of the mouth in the 
buccal cavity totaling four 200 μg tablets. Using more than 
4 tablets simultaneously has not been studied and is therefore 
not advised. In addition, it is important to minimize the num-
ber of strengths available to patients at any time to prevent 
confusion and possible overdose. Once a successful dose has 
been established during the titration, patients should continue 
to take their dose as a single tablet of that given strength and 
must wait 4 hours before treating a new breakthrough pain 
episode. If more than 4 breakthrough cancer pain episodes 
occur per day, a dose readjustment of the maintenance opioid 
used for the persistent pain should be re-evaluated and 
Table 2   Adverse events occurring in 5% of patients in the 
placebo-controlled trials of fentanyl buccal tablet in opioid-tolerant 
cancer patients experiencing breakthrough pain
Adverse events (%) Study n = 123 Study n = 125
Nausea 27 (22) 16 (13)
Dizziness 27 (22) 14 (11)
Headache 18 (15) 8 (6)
Fatigue 15 (12) 10 (8)
Constipation 10 (8) 7 (6)
Vomiting 13 (11) 8 (6)
Somnolence 12 (10) NR
Asthenia 9 (7) NR
After30,31
Abbreviation: NR, not reported.Journal of Pain Research 2009:2 19
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possibly increased. Based on the dosing recommendation and 
safety information, prior feedback with the pain specialist 
is required. Before prescribing the formulation for a longer 
period of time (eg, up to 6 months with a quantity limit of 
4 units per day), the pain specialist should ensure that there 
is no drug diversion and/or illicit use of the agent.41
Safety precautions when using 
the FBT
Recently, the FDA issued a Public Health Advisory and a 
Healthcare Professional Sheet to alert healthcare profes-
sionals and consumers of potential safety issues with FBT 
after reports of isolated cases of deaths and other adverse 
events.42 The reported deaths all occurred as a result of 
improper patient selection, eg, use in opioid non-tolerant 
patients, improper dosing, and/or improper product 
substitution. Therefore, it is critical to follow product labeling 
when administering FBT. The tablet should not be used in 
patients who are not opioid tolerant and it is dangerous to use 
FBT for any short-term pain such as headache or migraine. 
Furthermore, physicians must be aware that FBT cannot 
be substituted for OTFC on a microgram base because, as 
demonstrated, FBT delivers more fentanyl to the blood than 
OTFC and, thus, dose-for-dose substitution can result in a 
fatal overdose. Therefore the following key points underline 
the need for appropriate patient selection, and proper dosing 
and administration of FBT in order to reduce the risk of 
respiratory depression.
In addition to carefully following dosing instructions and 
patient selection, the following criteria are to be observed in 
order to avoid potential respiratory depression (10 rules in 
breakthrough pain):
 1. FBT at any dosage should not be used in opioid non-
tolerant patients, ie, patients who are not taking around-
the-clock opioids.
 2. FBT should be used only for the labeled indication.
 3. FTB should not be prescribed for patients with acute 
pain, postoperative pain, headache/migraine, or sports 
injuries, even if they are deemed suitable recipients of 
other opioids on a PRN basis.
 4. Since FTB is not a generic version of OTFC, the buccal 
tablet should not be substituted for OTFC or any other 
fentanyl-containing products.
  5. For unrelieved breakthrough cancer pain, patients should 
not take more than 2 FBT tablets per breakthrough pain 
episode, except during dose titration.
  6. Patients must wait at least 4 hours before treating another 
breakthrough pain episode with FBT.
  7. In cases of more than 4 cancer pain breakthrough episodes 
per day, a readjustment of the maintenance opioid dose 
should be considered.
  8. FBT contains a highly potent opioid, which has the poten-
tial for respiratory depression especially when used in 
opioid-naïve patients. Respiratory depression can rapidly 
be reversed by the speciﬁ  c antagonist naloxone. When 
doing so, the dose of the antagonist should be titrated to 
effect in order to retain sufﬁ  cient analgesia.43
  9. Usually opioids are effective in treating breakthrough pain. 
In certain situations, however, (eg, neuropathic pain) these 
agents are not sufﬁ  cient to alleviate nociception. Then the 
non-speciﬁ  c NMDA antagonist ketamine (preferably as 
a nasal spray) presents an alternative solution.44
10. Finally, FBT is a schedule II agent, which has the 
potential for abuse, addiction and diversion when used 
in patients without cancer pain.
Conclusion
From a clinical perspective, FBT offers a number of advan-
tages over older agents used in breakthrough cancer pain. 
Compared with standard regular-release opiates, such as 
oxycodone or morphine, it has to be expected that the 
peak analgesic effect will occur with FBT before the other 
agents produce any signiﬁ  cant analgesic effect. Because 
FBT enhances bioavailability of fentanyl across the buccal 
mucosa, it is also the preferred rapid-onset opiate when a 
patient has difﬁ  culty swallowing and/or in situations where 
there is poor gastrointestinal absorption. Thus, drugs like 
FBT represent a new technology, which optimizes the ability 
to rapidly control breakthrough cancer pain and improve pain 
control, thereby improving quality of life. In spite of such 
recent advancement in the treatment of breakthrough pain, 
even when using FBT, challenges will remain as there is still 
scope for further optimization.
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